Peginterferon and ribavirin treatment for hepatitis C virus infection

doi:10.3748/wjg.v17.i4.419

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4720)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-2) series.

Item

Count

PDF

386

HTML

4181

Tables (1-2)

153

Sum=4720

Jan 28, 2011 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (38)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Jan 28, 2011; 17(4): 419-432
Published online Jan 28, 2011. doi: 10.3748/wjg.v17.i4.419

Peginterferon and ribavirin treatment for hepatitis C virus infection

Akihito Tsubota, Kiyotaka Fujise, Yoshihisa Namiki, Norio Tada

Akihito Tsubota, Kiyotaka Fujise, Yoshihisa Namiki, Norio Tada, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan

Author contributions: Tsubota A, Fujise K, Namiki Y and Tada N all generated the ideas and contributed to the writing of this manuscript.

Correspondence to: Akihito Tsubota, MD, PhD, Associate Professor, Institute of Clinical Medicine and Research, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan. atsubo@jikei.ac.jp

Telephone: +81-4-71641111 Fax: +81-4-71668638

Received: June 28, 2010
Revised: August 2, 2010
Accepted: August 9, 2010
Published online: January 28, 2011

Abstract

Pegylated interferon α (IFNα) in combination with ribavirin is currently recommended as a standard-of-care treatment for chronic hepatitis C virus (HCV) infection. This combination therapy has drastically improved the rate of sustained virological response, specifically in difficult-to-treat patients. Recently, individualized treatment, such as response-guided therapy, is being developed based on host-, HCV- and treatment-related factors. Furthermore, modified regimens with currently available medications, novel modified IFNα and ribavirin or combinations with specifically targeted antiviral therapy for HCV agents, are currently being investigated. The purpose of this review is to address some issues and epoch-making topics in the treatment of chronic HCV infection, and to discuss more optimal and highly individualized therapeutic strategies for HCV-infected patients.

Keywords: Pegylated interferon α, Ribavirin, Chronic hepatitis C virus infection, Difficult-to-treat patient, Individualized treatment, Response-guided therapy, Specifically targeted antiviral therapy for hepatitis C virus